Evidence map›Paper›PMID 24284412›Full record

ArticleMolecular & cellular proteomics : MCP2014

Amyloid beta a4 precursor protein-binding family B member 1 (FE65) interactomics revealed synaptic vesicle glycoprotein 2A (SV2A) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) as new binding proteins in the human brain.

Fabian M Nensa, Martin H D Neumann, Andreas Schrötter, Andre Przyborski, Thomas Mastalski, Sergej Susdalzew, Christina Looβe, Stefan Helling, Fouzi El Magraoui, Ralf Erdmann and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. FE65: a hub for neurodevelopment.Neural regeneration research · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Synaptic vesicle protein 2: A multi-faceted regulator of secretion.Seminars in cell & developmental biology · 2019
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Puzzling Out Synaptic Vesicle 2 Family Members Functions.Frontiers in molecular neuroscience · 2017
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Fabian M NensaFunctional Proteomics, Medizinisches Proteom-Center, Ruhr-University Bochum, D-44801 Bochum, Germany;
Martin H D Neumann
Andreas Schrötter
Andre Przyborski
Thomas Mastalski
Sergej Susdalzew
Christina Looβe
Stefan Helling
Fouzi El Magraoui
Ralf Erdmann
Helmut E Meyer
Julian Uszkoreit
Martin Eisenacher
Jaehong Suh
Suzanne Y Guénette
Nelli Röhner
Donat Kögel
Carsten Theiss
Katrin Marcus
Thorsten Müller
Ruhr University Bochum · DEMaineGeneral Medical Center · USGoethe University Frankfurt · DEMassachusetts General Hospital · USLeibniz Institute for Analytical Sciences - ISAS · DE

Funding

ROLE OF HFE65 PROTEINS IN ALZHEIMER'S DISEASE.R01AG015903 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GUENETTE, SUZANNE Y · 2000 to 2009
$2.9M
NIA NIH HHS AG15903NIA NIH HHS R01 AG015903
6 · The paper itself

Abstract

FE65 is a cytosolic adapter protein and an important binding partner of amyloid precursor protein. Dependent on Thr668 phosphorylation in amyloid precursor protein, which influences amyloidogenic amyloid precursor protein processing, FE65 undergoes nuclear translocation, thereby transmitting a signal from the cell membrane to the nucleus. As this translocation may be relevant in Alzheimer disease, and as FE65 consists of three protein-protein interaction domains able to bind and affect a variety of other proteins and downstream signaling pathways, the identification of the FE65 interactome is of central interest in Alzheimer disease research. In this study, we identified 121 proteins as new potential FE65 interacting proteins in a pulldown/mass spectrometry approach using human post-mortem brain samples as protein pools for recombinantly expressed FE65. Co-immunoprecipitation assays further validated the interaction of FE65 with the candidates SV2A and SERCA2. In parallel, we investigated the whole cell proteome of primary hippocampal neurons from FE65/FE65L1 double knockout mice. Notably, the validated FE65 binding proteins were also found to be differentially abundant in neurons derived from the FE65 knockout mice relative to wild-type control neurons. SERCA2 is an important player in cellular calcium homeostasis, which was found to be up-regulated in double knockout neurons. Indeed, knock-down of FE65 in HEK293T cells also evoked an elevated sensitivity to thapsigargin, a stressor specifically targeting the activity of SERCA2. Thus, our results suggest that FE65 is involved in the regulation of intracellular calcium homeostasis. Whereas transfection of FE65 alone caused a typical dot-like phenotype in the nucleus, co-transfection of SV2A significantly reduced the percentage of FE65 dot-positive cells, pointing to a possible role for SV2A in the modulation of FE65 intracellular targeting. Given that SV2A has a signaling function at the presynapse, its effect on FE65 intracellular localization suggests that the SV2A/FE65 interaction might play a role in synaptic signal transduction.

Indexed as

Protein Interaction MapsAnimalsBrainCells, CulturedEmbryo, MammalianHEK293 CellsHumansImmunoprecipitationMembrane GlycoproteinsMiceMice, KnockoutNerve Tissue ProteinsNeuronsNuclear ProteinsProtein BindingSynapsesAPBB1 protein, humanMembrane GlycoproteinsNerve Tissue ProteinsNuclear ProteinsSV2A protein, human

Identifiers

PMID24284412
PMCPMC3916648
OpenAlexW2150991220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.